Dr. Reidy-Lagunes on Sequencing Therapies for Patients With NETs

Diane Reidy-Lagunes, MD
Published: Wednesday, Sep 28, 2016



Diane Reidy-Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses sequencing various treatments for patients with neuroendocrine tumors (NETs).

There are currently no trials aimed at determining optimal sequence of therapies, Reidy-Lagunes explains. To stay parallel with NCCN guidelines, she often chooses somatostatin analogs as a first-line treatment for patients. This is because this type of therapy is said to be well-tolerated with a significant disease-control rate.

An additional option includes everolimus (Afinitor) for patients with pancreatic, lung, and gastrointestinal NETs as a second-line therapy. For pancreatic NETs specifically, sunitinib (Sutent) and cytotoxic therapies are also available. Peptide receptor radionuclide therapy is a potential treatment for patients with midgut NETs, though researchers are unsure where that would fit in the treatment course, Reidy-Lagunes says.


Diane Reidy-Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses sequencing various treatments for patients with neuroendocrine tumors (NETs).

There are currently no trials aimed at determining optimal sequence of therapies, Reidy-Lagunes explains. To stay parallel with NCCN guidelines, she often chooses somatostatin analogs as a first-line treatment for patients. This is because this type of therapy is said to be well-tolerated with a significant disease-control rate.

An additional option includes everolimus (Afinitor) for patients with pancreatic, lung, and gastrointestinal NETs as a second-line therapy. For pancreatic NETs specifically, sunitinib (Sutent) and cytotoxic therapies are also available. Peptide receptor radionuclide therapy is a potential treatment for patients with midgut NETs, though researchers are unsure where that would fit in the treatment course, Reidy-Lagunes says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x